Open an account

BioCorRx

BICX · OTC

$0.2402−$0.0098 (−3.92%)TodayMarket closed ·
No price history for this range.

About BICX

BioCorRx, Inc. engages in the provision of alcoholism and opioid addiction treatment. The company is headquartered in Anaheim, California. The company went IPO on 2010-08-31. The firm is engaged in offering treatment for substance use and other related disorders. Its Beat Addiction Recovery is a substance use disorder recovery program that typically includes its Cognitive Behavioral Therapy (CBT) modules along with peer support via mobile app, along with medication prescribed by an independent treating physician under their discretion. The UnCraveRx Weight Loss Program is also a medication-assisted weight-loss program that includes access to concierge on-demand wellness specialists, nutritionists, fitness experts, and personal support from behavioral experts. The company also controls BioCorRx Pharmaceuticals Inc., a clinical-stage drug development subsidiary, which is seeking FDA approval for BICX104, an implantable naltrexone pellet for the treatment of alcohol and opioid use disorders. The company is also engaged in the establishment of alcoholism and opioid addiction rehabilitation and treatment centers.

Employees
0
Headquarters
Anaheim, California
Listed
Aug 31, 2010
Sector
Health Care
Industry
Health Care Providers & Services
Website
biocorrx.com

BICX key statistics

Market cap
7.15M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.45K
Volume
1.00K
Open price
$0.2402
High today
$0.2402
Low today
$0.2402
52 Week high
$1.28
52 Week low
$0.152

BioCorRx (BICX) at a glance

As of Oct 20, 2026, BioCorRx (BICX) shares are priced at $0.2402, giving the company a market cap of 7.15M and a price-to-earnings ratio of 0.00.

Volume so far is 1.00K shares, below the average of 1.45K shares a day.

Over the past year BioCorRx has ranged from $0.152 to $1.28, and now sits 8% of the way up that range.

BioCorRx met or beat analyst EPS estimates in 1 of the last 4 quarters. In Q4 FY25 it reported $0.05 per share against an estimate of -$0.0612.

BICX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 1 of the last 4 quarters, by 181.7% on average.

  1. Q3 FY23: reported -$0.10 per share against an estimate of $0.00
  2. Q4 FY24: reported -$0.08 per share against an estimate of $0.00
  3. Q3 FY25: reported -$0.09 per share against an estimate of -$0.0612
  4. Q4 FY25: reported $0.05 per share against an estimate of -$0.0612

BICX news

  • Press releaseGlobe Newswire

    BioCorRx Inc. to Present at the Life Sciences Virtual Investor Forum December 11th

  • Press releaseGlobe Newswire

    Diamond Equity Research Initiates Coverage on BioCorRx®, Inc. (OTCQB: BICX)

Similar companies

Companies in the same industry as BioCorRx

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.